Fatigue in MS: From Invisible to Measurable (NCT07182903) | Clinical Trial Compass
CompletedNot Applicable
Fatigue in MS: From Invisible to Measurable
Netherlands34 participantsStarted 2025-10-27
Plain-language summary
Fatigue is one of the most common and burdensome symptoms of MS, but its precise cause remains unknown, and an effective treatment is lacking. Previous research has shown that the progression of MS is associated with a higher presence of a specific type of T-cell, the cytotoxic CD4+ T-cells, which play a role in the immune system.
The aim of this study is to investigate whether these cells can also be linked to fatigue in people with MS.
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of relapsing remittion, primary progressive or secondary progressive MS
* Age: 18-60 years
* Ability to perform the foot-tapping task
* Ability to walk at least 20 meters (with or without walking aid)
Exclusion Criteria:
* Dimethyl fumarate, fingolimod or alemtuzumab treatment, since these medications have a strong influence on the immune system As a result of these treatments, there are few to no immune cells circulating in the blood, meaning we cannot find our population of interest in the blood.
* Change in medication 6 weeks before the start of the study (including medication not related to MS) - MS relapse within 6 weeks of the start of the study
* Had an infection in the last month - Received a vaccination in the last 14 days - Pregnant or pregnancy in the last 6 months
* Having a psychiatric disorder
* Having a neurological disorder other than MS
* Having cognitive or communicative problems that makes it hard to follow instructions
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Correlation between percentage of cytotoxic CD4+ T cells and FSS score
Timeframe: Day 1
2
Correlation between percentage of cytotoxic CD4+ T cells and MFIS score
Timeframe: Day 1
3
Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping frequency decrease
Timeframe: Day 1
4
Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping amplitude decrease